Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis

Guselkumab is an anti‐interleukin‐23 human monoclonal antibody effective in treating psoriatic arthritis (PsA). To characterize the pharmacokinetics (PKs) and exposure‐response relationship of guselkumab in PsA, population PKs, and exposure‐response modeling, analyses were conducted using data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yang, Miao, Xin, Hsu, Chyi‐Hung, Zhuang, Yanli, Kollmeier, Alexa, Xu, Zhenhua, Zhou, Honghui, Sharma, Amarnath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932692/
https://www.ncbi.nlm.nih.gov/pubmed/34854241
http://dx.doi.org/10.1111/cts.13197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932692/
https://www.ncbi.nlm.nih.gov/pubmed/34854241
http://dx.doi.org/10.1111/cts.13197

Ejemplares similares